This is a routine IP announcement with no near-term valuation catalyst. Monitor the Acclaim-3 clinical trial for data readouts and the company's cash runway disclosures. The stock has historically been highly volatile with no positive drift following previous events.
Price Chart
Executive Summary
Genprex announced that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering Reqorsa Gene Therapy in combination with PD-1/PD-L1 antibodies for non-small cell and small cell lung cancer. This expands the company's international patent portfolio but is a routine IP milestone with no new clinical data or financial terms disclosed.
Key Facts
- Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering Reqorsa Gene Therapy (quaratusugene ozeplasmid) combined with PD-1 or PD-L1 antibodies for lung cancer treatment.
- Similar patents have previously been granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore, Europe, Korea, Australia and Israel.
- The patent provides IP protection for the Acclaim-3 clinical trial evaluating these combinations.
- No financial terms, new clinical data, or changes to the company's financial condition were disclosed.
- The company is a $6M market cap clinical-stage biotech with no approved products.
Financial Impact
No financial terms disclosed; patent allowance has no direct revenue impact at this pre-revenue stage.
Risk Factors
- Clinical trial failure risk remains the primary binary catalyst; patent protection does not derisk clinical outcomes.
- Company faces going concern risk and Nasdaq listing compliance risks as noted in forward-looking statements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-021262 |
| Document: 0001437749-26-021262-index-headers.html | 0001437749-26-021262 |
| Document: 0001437749-26-021262-index.html | 0001437749-26-021262 |
| Document: 0001437749-26-021262.txt | 0001437749-26-021262 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $2.05 | awaiting T+60 | — | $1.96 (−4.63%) |
Aug 18, 2026 10w ago | 8-K | $3.95 | awaiting T+60 | — | $1.96 (−50.51%) |
Aug 3, 2026 12w ago | 8-K | $4.75 | awaiting T+60 | — | $1.96 (−58.84%) |
Jul 14, 2026 15w ago | 8-K | $0.4632 $0.1191 | ▲ +74.29% | ▲ +77.67% | $1.96 (−322.06%) |
Jun 22, 2026 18w ago | 8-K | $0.5501 $0.1550 | ▼ −71.82% | ▼ −73.12% | $1.96 (+255.39%) |
May 26, 2026 22w ago | 8-K | $16.98 $3.99 | ▼ −76.51% | ▼ −79.23% | $1.96 (−88.49%) |
May 14, 2026 23w ago | 8-K | $18.94 $4.19 | ▼ −77.88% | ▼ −81.47% | $1.96 (−89.68%) |
Apr 28, 2026 26w ago | 8-K | $20.35 $7.49 | ▼ −63.19% | ▼ −67.18% | $1.96 (−90.39%) |
Apr 21, 2026 27w ago | 8-K | $23.98 $7.67 | ▼ −68.02% | ▼ −73.86% | $1.96 (−91.85%) |
Mar 18, 2026 31w ago | 8-K | $2.01 $0.6540 | ▼ −67.46% | ▼ −78.99% | $1.96 (−2.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers